Hikma Launches First US Sodium Acetate With CGT Exclusivity
The Firm Plans Two Further Launches Of Different Concentrations
Executive Summary
Following on from a flurry of deal and launches, Hikma has released another product onto the US market with the first of its sodium acetate injections, bolstered by 180 days of Competitive Generic Therapy exclusivity.